Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in HFpEF with Pulmonary Vascular Disease (Phase 2b)
DRKS00013360Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in cor pulmonale, heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) comparing Macitentan with Placebo (2 arms). Started Dec 2017; status: terminated.
02
Drugs
macitentan
03
Conditions
cor pulmonaleheart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on DRKS00013360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013360.